IS8587A - Atorvastatin lyfjasamsetning - Google Patents

Atorvastatin lyfjasamsetning

Info

Publication number
IS8587A
IS8587A IS8587A IS8587A IS8587A IS 8587 A IS8587 A IS 8587A IS 8587 A IS8587 A IS 8587A IS 8587 A IS8587 A IS 8587A IS 8587 A IS8587 A IS 8587A
Authority
IS
Iceland
Prior art keywords
pharmaceutical combination
atorvastatin pharmaceutical
atorvastatin
combination
pharmaceutical
Prior art date
Application number
IS8587A
Other languages
English (en)
Inventor
Jóhannsson Fjalar
Original Assignee
Actavis Group Hf.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group Hf. filed Critical Actavis Group Hf.
Priority to IS8587A priority Critical patent/IS8587A/is
Priority to EP07849693A priority patent/EP2124899A2/en
Priority to PCT/IS2007/000024 priority patent/WO2008078341A2/en
Publication of IS8587A publication Critical patent/IS8587A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IS8587A 2006-12-27 2006-12-27 Atorvastatin lyfjasamsetning IS8587A (is)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IS8587A IS8587A (is) 2006-12-27 2006-12-27 Atorvastatin lyfjasamsetning
EP07849693A EP2124899A2 (en) 2006-12-27 2007-12-21 Stable pharmaceutical formulations of atorvastatin magnesium salt
PCT/IS2007/000024 WO2008078341A2 (en) 2006-12-27 2007-12-21 Stable pharmaceutical formulations of atorvastatin magnesium salt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS8587A IS8587A (is) 2006-12-27 2006-12-27 Atorvastatin lyfjasamsetning

Publications (1)

Publication Number Publication Date
IS8587A true IS8587A (is) 2008-06-28

Family

ID=39473858

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8587A IS8587A (is) 2006-12-27 2006-12-27 Atorvastatin lyfjasamsetning

Country Status (3)

Country Link
EP (1) EP2124899A2 (is)
IS (1) IS8587A (is)
WO (1) WO2008078341A2 (is)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2130819A3 (en) * 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Crystalline forms of atorvastatin magnesium

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307720A (pt) * 2002-02-14 2005-01-25 Ranbaxi Lab Ltd Formulações de atorvastatina estabilizadas com adições de metal alcalino, método para produzir uma formulação farmacêutica e estabilizar dita formulação
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
EP1833466A1 (en) * 2004-12-28 2007-09-19 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
US20100222405A1 (en) * 2005-05-03 2010-09-02 Yatendar Kumar Magnesium salts of hmg-coa reductase inhibitors
CA2631549A1 (en) * 2005-11-29 2007-06-07 Biocon Limited Polymorphs of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l-heptanoic acid magnesium salt (2: 1)
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
CN101516842A (zh) * 2006-05-11 2009-08-26 百康有限公司 阿托伐他汀镁晶型b4及其方法

Also Published As

Publication number Publication date
EP2124899A2 (en) 2009-12-02
WO2008078341A2 (en) 2008-07-03
WO2008078341A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
LTPA2018005I1 (lt) Farmacinė kompozicija
DK2041139T3 (da) Farmaceutiske forbindelser
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0719393A2 (pt) Composição farmacêutica
RU2398586C3 (ru) Фармацевтическая композиция
DK1957073T3 (da) Lægemiddel
DK2399580T3 (da) Farmaceutiske doseringsformer
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0920521A2 (pt) combinação farmacêutica
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK1986650T3 (da) Manipulationssikre doserignsformer
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
AT504580A3 (de) Scan-einrichtung
ATE546437T1 (de) Aminomethyl-4-imidazole
DK2120884T3 (da) Farmaceutisk sammensætning
DK2035369T3 (da) Terapeutiske
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE502007000361D1 (de) Stanznieteinheit
DE102006045567A8 (de) Crimpstabilisierung
BRPI0716742A2 (pt) Lactamas terapêuticas
DE112007003147A5 (de) Rohr-Biegevorrichtung
DE502007001652D1 (de) Notöltank